Antibiotics

Researchers found that the use of the treatment algorithm for staphylococcal bacteremia shortens therapy without compromising outcomes.

Emily Heil, PharmD, BCPS-AQ ID, sheds light on one of the standards of new antibiotic stewardship regulations: all antibiotic orders should include indication for use.

Whether the oft-repeated pattern of initial drug success followed by increasing resistance plays out in the future for many drugs remains to be seen.

David Andes, MD, shares the half-life and dosing intervals for a new long-acting echinocandin.

Dr. Maria Bye, an epidemiologist at the Minnesota Department of Health shares some unsettling news when it comes to C. difficile: dentists’ prescribing habits may be contributing to CDI incidence.

Steven Gelone, PharmD, shares the topline data yielded from the LEAP-1 study.

Patrick Horn, MD, PhD, explains why eravacycline is a unique antibiotic and how it stands up against many different types of pathogens, including those that are multidrug-resistant.

James S. Lewis, PharmD, FIDSA, addresses the issues that surround current antibiotic development.

A new antibiotic susceptibility testing device developed by scientists at the National Institute of Standards and Technology could offer doctors a faster way to prescribe the right antibiotic.

Experts debate the use of cephalosporins in patients who are allergic to penicillins who have not undergone a prior allergy evaluation.

Surotomycin fails to show benefit over vancomycin for the treatment of Clostridium difficile infection in a phase 3 trial.

Contagion® will be providing exclusive coverage on the conference, and so, keep your eyes peeled for session coverage and interviews with some of the key presenters.

William D. O’Riordan, MD, FACEP, explains what makes iclaprim a unique antibiotic.

One single-center study demonstrates that for patients with hospital stays of 1 week or less, reporting bacteriology results sooner may lead to earlier discharge.

David Huang, PhD, MD, explains what the next steps are for iclaprim, an antibiotic developed to treat patients with acute bacterial skin and skin structure infections.

UCLA researchers have shown that using molecular methods to predict susceptibility testing could serve as a new way to monitor drug-resistant gonorrhea.

Alan Gross, PharmD, shares the drawbacks of some of the current prediction tools used for pneumonia.

WHO report confirms that “the world is running out of antibiotics” to treat resistant priority pathogens

As practitioners continue to mistake the worsening of asthma symptoms for bacterial respiratory infections, more antibiotics are being prescribed, many times, inappropriately.

Daniel Pilch, PhD, explains how the health care system must change in order to battle antibiotic resistance.

Antimicrobial stewardship and antimicrobial susceptibility testing (AST) remain critical in the race against antimicrobial resistance.

Alan Gross, PharmD, shares how an early diagnosis of multidrug-resistant pneumonia can work towards improving patient outcomes.

Meghan Jeffres, PharmD, shares what should be considered when considering the incorporation of penicillin skin testing into a health care facility.

Diagnostic methods make all the difference in efforts against antimicrobial resistance.

Edmond LaVoie, PhD, shares different approaches that can be used to forestall the development of antibiotic resistance.

Alan Gross, PharmD, BCPS-AQID, shares how the Society of Infectious Diseases Pharmacists is working to improve antibiotic stewardship programs in long-term care facilities.

To paraphrase Anthelme Brillat-Savarin, “we are what we eat”—Especially when it comes to antimicrobials and food-producing animals.

Jason Pogue, PharmD, BCPS-ID, explains the clinical significance of his research team’s findings regarding the use of ceftolozane-tazobactam to treat Pseudomonas infections.

Edmond LaVoie, PhD, explains how his team’s approach can be applied in the development of novel drugs for the treatment of drug-resistant infections caused by Gram-negative and Gram-positive bacteria.

A team of researchers discover that Klebsiella pneumoniae is not the only culprit behind life-threatening healthcare-associated infections: there are two other Klebsiella species that share the blame.